Case Report

Topotecan-induced Bronchiolitis

Authors: Colin C. Edgerton, MD, Matthew Gilman, MD, Bernard J. Roth, MD

Abstract

Topotecan HCl is an antitumor drug exhibiting topoisomerase I-inhibitory activity. Topotecan is used in the treatment of metastatic carcinoma of the ovary and as second-line treatment of small-cell lung cancer. Reported dose-limiting adverse reactions to topotecan are primarily hematologic in nature. To date, only one other case of lung toxicity in a patient taking topotecan has been reported. The authors describe the development of obliterative bronchiolitis, as evidenced by radiographic and pulmonary function testing abnormalities, in a 61-year-old woman who presented with dyspnea, and who was receiving topotecan for peritoneal carcinomatosis.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001;19:3967–3975.
 
2. Rossi SE. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics2000;20:1245–1259.
 
3. Lynch DA. Imaging of small airways diseases. Clin Chest Med 1993;14:623–634.
 
4. Arakawa H, Kurihara Y, Niimi H, et al. Bronchiolitis obliterans with organizing pneumonia versus chronic eosinophilic pneumonia: high-resolution CT findings in 81 patients. AJR Am J Roentgenol2001;176:1053–1058.
 
5. Murray JF, Nadel JA. Textbook of Respiratory Medicine. 3rd ed. Philadelphia, WB Saunders Company, 2000, pp 1362–1364.
 
6. Sato P, Madtes DK, Thorning D. Bronchiolitis obliterans caused by Legionella pneumophila. Chest1985;87:840 –842.
 
7. Coultas DB, Samet JM, Butler C. Bronchiolitis obliterans due to Mycoplasma pneumoniae. West J Med 1986;144:471–474.
 
8. King TE Jr, Mortenson RL. Cryptogenic organizing pneumonitis: the North American experience.Chest 1992;102(1 suppl):8S–13S.
 
9. Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease. Am Rev Respir Dis1986;133:321–340.
 
10. Lehne G, Lote K. Pulmonary toxicity of cytotoxic and immunosuppressive agents. Acta Oncol1990;29:113–124.